Skip to content

Reported May 7, 2026 · Before market open

Revenue estimate$7.5M
EPS estimate-$0.56

Next report

Aug 6, 2026 (in a month)
Revenue estimate$2.2M
EPS estimate-$0.96

Financials

Q1 2026

Income statement

See full
Revenue$20.0M
Operating income-$24.2M+10.7%
Net income-$19.9M+17.5%
EPS (diluted)-$0.42+38.2%

Balance sheet

See full
Cash & equivalents$78.1M+35.5%
Total debt$10.8M+37.8%
Total equity$471.5M+65.0%
Total assets$497.6M+64.7%

Cash flow

See full
Operating cash flow-$13.1M+35.5%
CapEx$86.0K-70.4%
Free cash flow-$13.1M+36.0%

Valuation & ratios

Valuation

as of 06/25/26
See full
Market cap$1.86B+309%
Enterprise value$1.79B+352%

Returns & leverage

See full
Return on equity-28.3%
Debt / equity0.0×
Current ratio27.1×-3.9×

Versus estimates

Ask the moment Rapport Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Rapport Therapeutics, Inc. report Q1 2026 earnings?
Rapport Therapeutics, Inc. (RAPP) reported Q1 2026 earnings on May 7, 2026 before market open.
What were Rapport Therapeutics, Inc.'s Q1 2026 revenue and EPS?
Rapport Therapeutics, Inc. reported revenue of $20.0M and diluted EPS of $-0.42 for Q1 2026.
Did Rapport Therapeutics, Inc. beat estimates in Q1 2026?
Revenue beat the consensus estimate of $7.5M by $12.5M. EPS beat the consensus estimate of $-0.56 by $0.14.
How did Rapport Therapeutics, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS grew 38.2% from $-0.68.
Where can I find Rapport Therapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-210324) and the 10-Q periodic report (0001193125-26-210355) directly on SEC EDGAR. The filing index links above go to sec.gov.